Reshoring a pharmaceutical plant takes years

Washington can announce a tariff. It cannot announce a qualified fill-finish line. After a spring threat of 100 percent duties on branded pharmaceutical imports — later bargained toward onshoring agreements — counsel and supply chiefs are doing the unglamorous work: mapping APIs, packaging, and device components that still run through India and China.

The realistic timeline is not July. It is a sequence of facility qualification, FDA inspection, and second-source chemistry that takes three to seven years for anything complex. Trade lawyers are watching USMCA talks, Section 232 refinements, and the first wave of onshoring applications at Commerce, because those will set precedent. They are also watching Beijing and Delhi. Countermeasures on raw materials would move the bottleneck from the plant gate to the molecule.

China+1 has, in pharma as in electronics, become multi-region redundancy. That is more expensive. It is also, finally, being treated as a cost of doing business rather than a slide in the risk appendix.